Biogen Inc. is a leading company in the research and development of therapies for severe neurological, immunological, and rare disorders, with a market cap of approximately $28.8 billion. The company’s stock has outperformed the S&P 500, rising 41.9% over the past 52 weeks. Biogen’s Q4 financial results exceeded expectations, with revenue reaching $2.28 billion and adjusted EPS of $1.99. The company’s newer products contributed to this success, generating over $1 billion in annual revenue. Analysts project a 3.3% growth in diluted EPS for fiscal year 2026. Wall Street analysts currently rate Biogen as a “Moderate Buy.” Following the recent earnings release, HC Wainwright & Co. raised its price target to $228, suggesting further potential upside for the stock.

Read more at Barchart: What Are Wall Street Analysts’ Target Price for Biogen Stock?